BLACK WEEKSFlakonai −15% · rinkiniai −10% · kita −5%su koduNemokamas siuntimas Vokietijoje nuo €200

Šis puslapis išverstas automatiškai ir jame gali būti klaidų. Ar lietuvių kalba yra jūsų gimtoji? Mielai sulauksime jūsų atsiliepimų ir pataisymų.Siųsti atsiliepimą

The Peptide Desk The Peptide Desk
Insulin Glargin U300 (Toujeo), produkto nuotrauka
Medication

Insulin Glargin U300 (Toujeo)

Medication

  • Siunčiame iš Vokietijos

Užsakymas

Vieneto kaina - Nemokamas siuntimas Vokietijoje nuo 200 € Black Weeks metu
  • DHL su sekimu
  • Diskreti pakuotė

4.6 iš 5 TrustpilotAtsiliepimų: 73

Trumpai

Insulin Glargin U300 (Toujeo) skaičiais

Pagrindiniai rodikliai iš mūsų žinyno.

Visas žinyno įrašas
Class
Long-acting basal insulinanalogue
Use
Subcutaneousonce daily, pen only
Sizes
1.5ml/450iu1 size in the shop

Produktui Insulin Glargin U300 (Toujeo) laboratorinės analizės dar nėra. Balsuoti už taiVisos laboratorinės analizės

Žinios

Viskas apie Insulin Glargin U300 (Toujeo)

FAQ

Dažnai užduodami klausimai

Šaltiniai kiekvienam atsakymui: žinyno įrašas

Dar turite klausimų?

Parašykite mums, mūsų komanda jums padės.

How does U300 differ from U100?

Only the concentration: 300 instead of 100 units per millilitre, the same compound. The smaller depot releases it more evenly. In a 36-hour clamp level and effect ran flatter over 24 hours and tight glucose control lasted a median of about 30 hours, around 5 hours longer than with U100.

Why is a regular insulin syringe dangerous?

Regular insulin syringes are calibrated for U-100. With U300 solution the same mark holds three times the amount and you cannot see it. In the FDA drug database the 300 units/ml version is only listed as a prefilled injector with 1.5 or 3 ml, not as a vial.

Is Insulin Glargine U300 approved?

Yes. Drugs@FDA lists the 300 units/ml version since 25 February 2015. ChEMBL lists the compound insulin glargine with first approval in 2000. Everything here is the state of research, not a recommendation.

What did the EDITION trials show?

Same glucose control, less hypoglycaemia at night. In EDITION 1 (807 participants) 36 instead of 46 percent had night-time hypoglycaemia. The pooled analysis of EDITION 1 to 3 with 2,496 people found 31 percent less night-time and 14 percent less around-the-clock hypoglycaemia. Severe episodes stayed rare (2.3 versus 2.6 percent).

Does U300 need more units?

Slightly. In EDITION 2 U300 needed about 10 percent more units than U100 for the same reduction of the long-term value. Weight gain was lower with U300.

Does the time of day matter?

In EDITION 4 with 549 people with type 1 diabetes the result was the same in the morning and in the evening, including hypoglycaemia. Fewer night-time episodes than with U100 were only seen there in the first eight weeks, weight gain was lower.

Susiję

Susiję produktai